XNK: XNK Therapeutics AB: XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September
XNK Therapeutics AB today announced that two posters, regarding bladder cancer and acute myeloid leukemia (AML) respectively, will be presented at the 20th Meeting of the Society for Natural Immun...
Read full article »
XNK is a Switzerland-based clinical-stage biotechnology company that researches and develops novel NK cell-based therapies for the treatment of cancer.
Read more